{
    "root": "34a0701f-5154-611d-e063-6294a90a1367",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ONDANSETRON",
    "value": "20250508",
    "ingredients": [
        {
            "name": "ONDANSETRON HYDROCHLORIDE",
            "code": "NMH84OZK2B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7774"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "ondansetron tablets indicated prevention nausea vomiting associated : highly emetogenic cancer chemotherapy , including cisplatin greater equal 50 mg/m2 initial repeat courses moderately emetogenic cancer chemotherapy radiotherapy patients receiving either total body irradiation , single high-dose fraction abdomen , daily fractions abdomen ondansetron tablets also indicated prevention postoperative nausea and/or vomiting .",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "2.1 recommended regimens adult pediatric patients described table 1 table 2 , respectively . corresponding doses ondansetron tablets , ondansetron orally disintegrating tablets ondansetron oral solution may used interchangeably . table 1 : adult recommended regimen prevention nausea vomiting indication regimen highly emetogenic cancer chemotherapy single 24 mg dose administered 30 minutes start single-day highly emetogenic chemotherapy , including cisplatin greater equal 50 mg/m2 moderately emetogenic cancer chemotherapy 8 mg administered 30 minutes start chemotherapy , subsequent 8 mg dose 8 hours first dose . administer 8 mg twice day ( every 12 hours ) 1 2 days completion chemotherapy . radiotherapy total body irradiation : 8 mg administered 1 2 hours fraction radiotherapy day . single high-dose fraction radiotherapy abdomen : 8 mg administered 1 2 hours radiotherapy , subsequent 8 mg doses every 8 hours first dose 1 2 days completion radiotherapy . daily fractionated radiotherapy abdomen : 8 mg administered 1 2 hours radiotherapy , subsequent 8 mg doses every 8 hours first dose day radiotherapy given . postoperative 16 mg administered 1 hour induction anesthesia . table 2 : pediatric recommended regimen prevention nausea vomiting indication regimen moderately emetogenic cancer chemotherapy 12 17 years age : 8 mg administered 30 minutes start chemotherapy , subsequent 8 mg dose 8 hours first dose . administer 8 mg twice day ( every 12 hours ) 1 2 days completion chemotherapy . 4 11 years age : 4 mg administered 30 minutes start chemotherapy , subsequent 4 mg dose 4 8 hours first dose . administer 4 mg three times day 1 2 days completion chemotherapy . 2.2 hepatic impairment patients severe hepatic impairment ( child-pugh score 10 greater ) , exceed total daily dose 8 mg [ ( 8.6 ) , pharmacology ( 12.3 ) ] .",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "ondansetron tablets usp , 4 mg white off-white , oval shaped , film-coated tablets debossed \u2018 f \u2019 one side \u2018 91 \u2019 side . bottles 30 bottles 500 bottles 1,000 1 x 3 unit-dose tablets 10 x 10 unit-dose tablets ondansetron tablets usp , 8 mg yellow colored , oval shaped , film-coated tablets debossed \u2018 f \u2019 one side \u2018 92 \u2019 side . bottles 30 bottles 500 bottles 1,000 1 x 3 unit-dose tablets 10 x 10 unit-dose tablets ondansetron tablets usp , 24 mg pink colored , oval shaped , film-coated tablets debossed \u2018 c \u2019 one side \u2018 71 \u2019 side . unit-dose packs 1 tablet store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . protect light .",
    "adverseReactions": "ondansetron tablets contraindicated patients : known hypersensitivity ( e.g . , anaphylaxis ) ondansetron components formulation [ ( 6.2 ) ] receiving concomitant apomorphine due risk profound hypotension loss consciousness",
    "indications_original": "Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with:\n                  \n                  highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2\n  \ninitial and repeat courses of moderately emetogenic cancer chemotherapy\n  \nradiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen\n \n                  Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting.",
    "contraindications_original": "2.1 Dosage\n                  The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively.\n  \n                     \nCorresponding doses of ondansetron tablets, ondansetron orally disintegrating tablets and ondansetron oral solution may be used interchangeably.\n \n                  Table 1: Adult Recommended Dosage Regimen for Prevention of Nausea and Vomiting\n  \nIndication\n  \nDosage Regimen\n  \nHighly Emetogenic Cancer Chemotherapy\n  \nA single 24 mg dose administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin greater than or equal to 50 mg/m2\n  \nModerately Emetogenic Cancer Chemotherapy\n  \n8 mg administered 30 minutes before the start of chemotherapy, with a subsequent 8 mg dose 8 hours after the first dose.\n  \n                     \nThen administer 8 mg twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.\n  \nRadiotherapy\n  \nFor total body irradiation: 8 mg administered 1 to 2 hours before each fraction of radiotherapy each day.\n  \n                     \nFor single high-dose fraction radiotherapy to the abdomen: 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.\n  \n                     \nFor daily fractionated radiotherapy to the abdomen: 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for each day radiotherapy is given.\n  \nPostoperative\n  \n16 mg administered 1 hour before induction of anesthesia.\n \n                  \n                  Table 2: Pediatric Recommended Dosage Regimen for Prevention of Nausea and Vomiting\n  \nIndication\n  \nDosage Regimen\n  \nModerately Emetogenic Cancer Chemotherapy\n  \n12 to 17 years of age: 8 mg administered 30 minutes before the start of chemotherapy, with a subsequent 8 mg dose 8 hours after the first dose.\n  \n                     \nThen administer 8 mg twice  a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.\n  \n                     \n4 to 11 years of age: 4 mg administered 30 minutes before the start of chemotherapy, with a subsequent 4 mg dose 4 and 8 hours after the first dose.\n  \n                     \nThen administer 4 mg three times a day for 1 to 2 days after completion of chemotherapy.\n \n                  2.2 Dosage in Hepatic Impairment\n                  In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), do not exceed a total daily dose of 8 mg [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].",
    "warningsAndPrecautions_original": "Ondansetron Tablets USP, 4 mg are white to off-white, oval shaped, film-coated tablets debossed with \u2018F\u2019 on one side and \u201891\u2019 on the other side.\n  \n                     \n    Bottles of 30                            \n  \n    Bottles of 500                           \n  \n    Bottles of 1,000                        \n  \n    1 x 3 Unit-dose Tablets            \n  \n    10 x 10 Unit-dose Tablets        \n  \n                     \nOndansetron Tablets USP, 8 mg are yellow colored, oval shaped, film-coated tablets debossed with \u2018F\u2019 on one side and \u201892\u2019 on the other side.\n  \n                     \n    Bottles of 30                          \n  \n    Bottles of 500                        \n  \n    Bottles of 1,000                      \n  \n    1 x 3 Unit-dose Tablets          \n  \n    10 x 10 Unit-dose Tablets      \n  \n                     \nOndansetron Tablets USP, 24 mg are pink colored, oval shaped, film-coated tablets debossed with \u2018C\u2019 on one side and \u201871\u2019 on the other side.\n  \n                     \n    Unit-dose Packs of 1 Tablet   \n  \n                     \nStore at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. Protect from light.",
    "adverseReactions_original": "Ondansetron tablets are contraindicated in patients:\n                  \n                  known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation [see Adverse Reactions (6.2)]\n  \nreceiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness",
    "drug": [
        {
            "name": "ONDANSETRON",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7773"
        }
    ]
}